CJC-1295 vs CJC-1295 + Ipamorelin
CJC-1295 is a growth hormone-releasing hormone receptor agonist derived from the N-terminal 29-amino-acid fragment of human GHRH, sold both as the albumin-binding drug affinity complex form studied in phase 1 and phase 2 trials and as the unmodified short-acting form more accurately called modified GRF(1-29). The pairing adds ipamorelin, a pentapeptide agonist at the growth hormone secretagogue receptor GHS-R1a, on the rationale that engaging two separate receptor systems produces more growth hormone release than engaging either alone. That rationale rests on human work from the 1990s and early 2000s using other GHRH and secretagogue molecules. No published trial has administered CJC-1295 alone and CJC-1295 with ipamorelin in the same experiment, so the comparison between the single agent and the pair is indirect throughout, assembled from component-level studies and from reviews that describe the combination as a marketed product rather than a tested one.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published study has compared CJC-1295 given alone against CJC-1295 given with ipamorelin. Searches of PubMed and Europe PMC returned ten indexed records naming both peptides, and every one is a narrative or scoping review of unapproved peptides or a doping-control analytical method; none administered the pair, and none included a CJC-1295-only comparator arm. The closest thing to a combination-specific efficacy statement in the recent literature appears in a 2026 American Journal of Sports Medicine primer, which listed CJC-1295 combined with ipamorelin among the peptides it evaluated and reported significantly improved maximum tetanic tension in murine models of glucocorticoid-induced muscle loss, adding that the finding was limited to animal studies. The rodent experiment matching that description administered ipamorelin as a single agent alongside methylprednisolone in adult rats and included no GHRH analogue of any kind, so the underlying data describe the secretagogue on its own rather than the pair. What does exist is component-level and analogy-level evidence: the human phase 1 and phase 2 studies of the drug affinity complex form of CJC-1295, the pharmacological characterisation of ipamorelin as a secretagogue with growth hormone selectivity comparable to GHRH, and older human work showing that a growth hormone-releasing peptide combined with GHRH released more growth hormone than the sum of the two given separately. Those older synergy trials used earlier peptides rather than these two, and reviews that cite them for this pairing say so.
The 15 publications that cover both
- 01Review2026
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, et al. · Am J Sports Med · narrative review of injectable peptide therapies including BPC-157, thymosin beta-4, TB-500, CJC-1295 with ipamorelin, tesamorelin and GHK-Cu
This is the only located publication that treats CJC-1295 with ipamorelin as a single evaluated entity. It reported that the combination significantly improved maximum tetanic tension in murine models of glucocorticoid-induced muscle loss and stated that the finding was limited to animal studies. The authors concluded that indications, dosing, frequency and duration for these peptides remain unknown and that clinical use is not supported by present evidence.
- 02Animal in vivo2001
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats
Andersen NB, et al. · Growth Horm IGF Res · eight-month-old female rats given subcutaneous methylprednisolone, ipamorelin, or both in combination for three months, with in vivo maximum tetanic tension of the calf muscles and periosteal bone formation rate as endpoints
This is the rodent experiment that matches the tetanic-tension result attributed to the combination in later reviews, and it administered ipamorelin as a single agent with no GHRH analogue present. Maximum tetanic tension was significantly increased and periosteal bone formation rate increased approximately four-fold in animals given the glucocorticoid together with ipamorelin, compared with the glucocorticoid alone.
- 03Review2026
Peptide Supplements and Their Therapeutic Applications in Sports Medicine
Tewari K, et al. · Am J Sports Med · PRISMA-guided scoping review of six marketed peptides, including CJC-1295 and ipamorelin searched as separate terms, combined with musculoskeletal tissue terms
CJC-1295 and ipamorelin were searched and reported separately rather than as a pairing, and no combination study was retrieved. Sixty-seven per cent of the identified publications used preclinical animal models, and the human studies were few and mostly lacked robust controls. The authors concluded that claimed musculoskeletal benefits remained unsubstantiated and that documented risks included cardiovascular complications and insulin resistance.
- 04Review2026
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Dominikowski A, et al. · Front Endocrinol (Lausanne) · narrative review of GH-IGF-1 axis peptides obtained and self-administered outside regulated prescribing
The review listed CJC-1295, in both its drug affinity complex and unmodified forms, and ipamorelin as separate self-administered agents rather than as a studied combination, and set out an assessment approach for clinicians encountering patients using them. The authors described substantial uncertainty in the efficacy and safety data available for these compounds.
- 05Review2026
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
Villegas Meza AD, et al. · JBJS Rev · structured narrative review sorting injectable peptides published between 2020 and 2025 into five functional classes
Growth hormone axis agents, covering both the GHRH analogue and the secretagogue halves of this pairing, were classified as experimental. Only glucagon-like peptide-1 agonists were found to carry reproducible randomised evidence for a musculoskeletal indication, and the authors recommended confining use to approved agents and formal research protocols. Both components are prohibited in sport as growth hormone releasing agents.
- 06Review2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, Awan TM · Sports Med · narrative review separating regulator-approved peptide drugs from unapproved compounds marketed for musculoskeletal and performance use
CJC-1295 and ipamorelin were both placed in the unapproved category and discussed individually. The authors reported that adequately powered controlled trials supporting musculoskeletal or performance claims were absent for these agents, and that rigorous human safety data were scarce for most unapproved peptides in this class.
- 07Review2026
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, Lee SJ, Seeds WA · JAAOS Glob Res Rev · mechanistic review of therapeutic peptides grouped by signalling pathway and orthopaedic relevance
Ipamorelin, CJC-1295, tesamorelin, sermorelin and AOD-9604 were grouped together as growth hormone secretagogues described as activating IGF-1 signalling and satellite cell repair, without distinguishing single-agent from combined use. The authors stated that preclinical findings were promising but that clinical trials were currently lacking across the peptide classes reviewed.
- 08Review2026
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
Coutinho LFD, et al. · J Sports Med Phys Fitness · critical review of peptide and peptide-analogue use in recreational and professional sport and bodybuilding
Ipamorelin was described as a growth hormone secretagogue and CJC-1295 as a GHRH analogue, in separate categories. The authors noted that most published studies examined therapeutic applications under controlled dosing rather than the combined protocols common in bodybuilding, and identified cardiovascular strain, insulin resistance, dyslipidaemia and psychiatric instability as emerging risks alongside an unregulated supply chain with mislabelled or contaminated products.
- 09Review2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L · Int J Mol Sci · literature review of therapeutic peptides across aesthetic, metabolic and endocrine indications
The review found the strongest support for peptide agents in type 2 diabetes, obesity and skin applications, and named CJC-1295 and ipamorelin among endocrine-active peptides for which further study was required before they could be considered safe for human use. No combination data were cited.
- 10Review2026
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Mavrych V, Shypilova I, Bolgova O · Front Aging · narrative review searching PubMed, Scopus and regulatory databases from inception through January 2026 with named peptide search terms, selecting 20 primary sources covering nine peptides
CJC-1295 and ipamorelin were both searched as named terms and were grouped together under growth hormone modulation among nine peptides spanning different ageing interventions. The authors reported that non-approved peptides showed limited clinical evidence and lacked long-term safety data, and identified combination therapy effects as an explicit knowledge gap.
- 11In vitro2013
Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry
Kwok WH, et al. · Anal Bioanal Chem · mixed-mode anion exchange solid-phase extraction and high-resolution mass spectrometry for seven target peptides in horse plasma, including ipamorelin and CJC-1295, with in vitro metabolite identification
Both peptides were handled as analytes in one multi-residue method rather than as administered agents, with limits of detection estimated below 50 pg/mL for all seven targets. The method was demonstrated on plasma from thoroughbred geldings given TB-500, and the authors reported the first identification of in vitro metabolites for the other studied peptides in horses.
- 12Animal in vivo1998
Ipamorelin, the first selective growth hormone secretagogue
Raun K, et al. · Eur J Endocrinol · primary rat pituitary cells, anaesthetised rats and conscious swine, with pharmacological profiling using GHRP and GHRH antagonists
Ipamorelin released growth hormone with potency and efficacy similar to GHRP-6, and antagonist profiling showed it acted through a GHRP-like receptor rather than the GHRH receptor, establishing that the two halves of this pairing engage separate targets. Unlike GHRP-6 and GHRP-2, ipamorelin did not raise ACTH or cortisol above the levels seen after GHRH stimulation, even at doses far above the growth hormone threshold.
- 13Animal in vivo2002
Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro
Jiménez-Reina L, et al. · Histol Histopathol · young female rats treated chronically with ipamorelin or GHRH over 21 days, with pituitary cell monolayer cultures then challenged in vitro with ipamorelin, GHRP-6 or GHRH
The experiment ran a secretagogue arm and a GHRH arm in parallel and then cross-challenged the resulting pituitary cultures. Basal intracellular growth hormone content was lower in both the ipamorelin and GHRH groups than in saline controls. Only in cultures from ipamorelin-treated animals did in vitro ipamorelin, GHRP-6 or GHRH raise the percentage of somatotroph cells and intracellular growth hormone content.
- 14Animal in vivo1999
Pharmacological characterisation of a new oral GH secretagogue, NN703
Hansen BS, et al. · Eur J Endocrinol · rat pituitary cells, BHK cells expressing the human GHS receptor 1A, conscious swine, beagle dogs and a 14-day rat feeding study, characterising a secretagogue derived from ipamorelin
NN703, derived from ipamorelin, stimulated growth hormone release from rat pituitary cells with potency similar to GHRP-6, and that release was blocked by known secretagogue antagonists but not by a GHRH antagonist. The result reinforces that the secretagogue component of this pairing operates through a receptor distinct from the one CJC-1295 targets.
- 15Review2020
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
Sinha DK, et al. · Transl Androl Urol · review of growth hormone secretagogues, including the GHRH analogue sermorelin alongside GHRP-2, GHRP-6, ibutamoren and ipamorelin, in hypogonadal and eugonadal men
The review examined GHRH analogues and ghrelin-receptor secretagogues side by side as potential adjuncts for body composition, describing both classes as potent stimulators of growth hormone and IGF-1. The authors reported that a paucity of data on clinical effects limited any conclusion about the role of these agents, whether given singly or together.
Side by side.
| CJC-1295 | CJC-1295 + Ipamorelin | |
|---|---|---|
| Evidence maturity | Early clinical | Early clinical |
| Studies cited here | 16 | 15 |
| Published 2023 or later | 8 | 5 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A modified 29-amino-acid fragment of human GHRH. The form studied in the published human trials carries a maleimidopropionyl linker that forms a covalent complex with circulating albumin; the form usually sold without that linker is more accurately called modified GRF(1-29). | The same GHRH fragment supplied together with ipamorelin, a synthetic pentapeptide identified in the 1990s from a series lacking the central Ala-Trp dipeptide of GHRP-1. The two molecules are separate substances presented as one product. |
| Mechanism as described in the literature | Single receptor. Binds the GHRH receptor on pituitary somatotrophs. Frequent-sampling human work showed that continuous receptor stimulation raised basal and mean growth hormone while pulse frequency and amplitude remained essentially unchanged. | Two receptors. Ipamorelin acts at GHS-R1a, and antagonist profiling confirmed it does not work through the GHRH receptor. Human studies with other GHRH and secretagogue molecules found the combination released more growth hormone than the sum of each alone, and patient work showed the secretagogue arm of that synergy depended on intact hypothalamic input. |
| Size of the evidence base | Sixteen studies in this library: three human clinical, two animal, five reviews and six analytical or in vitro papers. Every human dataset concerns the drug affinity complex form and was generated between 2005 and 2009. | Fifteen studies in this library, all of them component-level or analogy-level. Nine are human clinical, but none administered the two peptides together; they cover CJC-1295 alone, ipamorelin alone, or GHRH combined with a different secretagogue. |
| Best-characterised finding | Prolonged, dose-dependent elevation of growth hormone and IGF-1 after single subcutaneous injection of the drug affinity complex form in healthy adults, with pulsatile secretion preserved and IGF-I remaining above baseline for weeks after repeated dosing. | There is no combination-specific finding. The best-characterised results belong to the components: the CJC-1295 pharmacodynamic studies above, the selectivity of ipamorelin for growth hormone release without ACTH or cortisol elevation, and the more-than-additive growth hormone response to GHRH plus a secretagogue in healthy men. |
| Human data | Small phase 1 and phase 2 studies in healthy adults, plus a serum proteomic analysis. No clinical outcome endpoint, no body composition endpoint and no randomised controlled trial of the unmodified form were located. | None for the combination. The human record consists of the CJC-1295 studies, a pharmacokinetic-pharmacodynamic model of intravenous ipamorelin in healthy volunteers, a randomised phase 2 trial of ipamorelin for postoperative ileus with gastrointestinal rather than growth hormone endpoints, and older synergy trials using different peptides. |
| Evidence maturity | Early clinical. Human pharmacodynamic data exist for one of the two marketed forms, and nothing beyond that. | Early clinical, and only by inheritance from the components. Recent reviews characterised the combination's clinical evidence base as absent rather than negative, and one named combination therapy effects as an explicit knowledge gap. |
| Recency of primary research | The primary human work is nearly two decades old. Publications since 2019 are predominantly anti-doping detection methods, in vitro metabolism studies and narrative reviews rather than new clinical data. | No primary research on the pairing has been published at any point. The 2026 literature engaging both names is entirely review and commentary, generated by clinical interest in a marketed product rather than by new experiments. |
| Basis of most marketing claims | Extrapolation from short-term growth hormone and IGF-1 elevation in healthy volunteers to body composition, recovery and sleep outcomes that were never measured, and frequent substitution of the unmodified form for the drug affinity complex form actually studied. | Extrapolation of the same kind, plus an additional inference: that synergy demonstrated between other GHRH and secretagogue molecules transfers to this specific pairing. A recent review's report of improved tetanic tension for the combination traces to a rodent experiment that administered ipamorelin alone. |
And what it does not.
The distinction between these two entries is a distinction between one untested product and another, not between a tested single agent and a tested combination. CJC-1295 has a genuine if narrow human dataset: small phase 1 and phase 2 studies of the albumin-binding form showing prolonged growth hormone and IGF-1 elevation with pulsatility preserved. Adding ipamorelin adds a second receptor system with its own respectable pharmacology, including a selectivity profile that spared ACTH and cortisol where earlier secretagogues did not. What is missing is any experiment putting the two arms side by side. The synergy argument is inherited from human trials in which GHRH was combined with a growth hormone-releasing peptide or with ghrelin, and those trials used neither of these molecules. No study has measured whether the pairing raises growth hormone more than CJC-1295 alone, whether any such difference persists with repeated exposure, or what it does to glucose tolerance, body composition or any clinical endpoint. Reviews published in 2026 describe the combination's evidence base as absent rather than negative, and that remains the accurate summary.
Common questions.
- Is there a published trial showing the pairing outperforms CJC-1295 on its own?
No. Searches of PubMed and Europe PMC returned no interventional study administering CJC-1295 together with ipamorelin, and therefore none containing a CJC-1295-only comparator arm. The ten indexed records naming both peptides are narrative or scoping reviews of unapproved peptides and one doping-control analytical method. Several of those reviews searched the two names separately and reported them in separate categories, which is itself an indication that no combination literature was retrieved.
- Where does the synergy argument for adding ipamorelin actually come from?
From human work published between 1990 and 2001 using different molecules. A growth hormone-releasing peptide given with GHRH to healthy men produced a growth hormone response greater than the sum of the individual responses, and a low dose of ghrelin combined with GHRH reproduced that pattern. A study in patients with hypothalamic-pituitary disconnection found the synergy disappeared when hypothalamic input was interrupted. Those results establish that the two receptor pathways interact, but they were generated with earlier peptides, not with CJC-1295 or ipamorelin.
- What did the rodent experiment behind the combination's muscle-strength claim actually test?
It tested ipamorelin by itself. Adult female rats received a glucocorticoid, ipamorelin, or both together for three months, and the group given the glucocorticoid with ipamorelin showed significantly increased maximum tetanic tension of the calf muscles and an approximately four-fold higher periosteal bone formation rate than the group given the glucocorticoid alone. No GHRH analogue was administered in that study, so the result describes the secretagogue component rather than the pairing that later reviews attribute it to.
- Does ipamorelin behave differently from the older growth hormone-releasing peptides?
In one specific respect, yes. In conscious swine, GHRP-6 and GHRP-2 both raised ACTH and cortisol, whereas ipamorelin did not raise either above the levels observed after GHRH stimulation, and that held at doses far above its growth hormone threshold. Antagonist profiling in rat pituitary cells confirmed that ipamorelin acts through a secretagogue-type receptor rather than the GHRH receptor. This selectivity is the original basis for describing ipamorelin as a selective secretagogue.
- Why do reviews keep discussing this pairing if nothing has been tested?
Because the clinical interest is driven by the market rather than by data. Publications from 2026 address the combination as a compounded or research-chemical product that patients are already self-administering, and set out how clinicians might assess someone using it. Those reviews also record the problems that accompany the unregulated supply chain, including mislabelled or contaminated preparations, and mass-spectrometric analysis of illicitly distributed growth-promoting products has found discrepancies between declared and actual content.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.